Segment and Geographic Area Information (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Net Sales and Operating Earnings by Segment

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

	Net Sales to External Customers (a)						Operating Earnings (a)
(in millions)	2023		2022		2021		2023		2022		2021
Established Pharmaceutical Products	$	5,066	$	4,912	$	4,718	$	1,206	$	1,049	$	889
Nutritional Products	8,154		7,459		8,294		1,333		706		1,763
Diagnostic Products (b)	9,988		16,469		15,526		2,433		6,640		6,237
Medical Devices (b)	16,887		14,802		14,485		5,306		4,436		4,533
Total Reportable Segments	40,095		43,642		43,023		$	10,278	$	12,831	$	13,422
Other	14		11		52
Total	$	40,109	$	43,653	$	43,075

________________________________________________________

(a)	In 2023 and 2022, foreign exchange unfavorably impacted net sales and operating earnings. In 2021, foreign exchange favorably impacted net sales and unfavorably impacted operating earnings.
(b)	2022 and 2021 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.

Schedule of Reconciliation of Operating Earnings to Earnings From Continuing Operations

(in millions)	2023		2022		2021
Total Reportable Segment Operating Earnings	$	10,278	$	12,831	$	13,422
Corporate functions and benefit plan costs	(308)		(509)		(801)
Net interest expense	(252)		(375)		(490)
Share-based compensation	(644)		(685)		(640)
Amortization of intangible assets	(1,966)		(2,013)		(2,047)
Other, net (c)	(444)		(943)		(1,233)
Earnings before Taxes	$	6,664	$	8,306	$	8,211

_______________________________________________________

(c) Other, net includes costs directly related to integrating acquired businesses and restructuring charges in 2023, 2022, and 2021. Charges and expenses for restructuring actions and other cost reduction initiatives were approximately $122 million in 2023, $265 million in 2022, and $375 million in 2021. Other, net in 2023 also includes charges of $100 million related to indefinite-lived intangible asset impairments, partially offset by income arising from fair value changes in contingent consideration related to previous business acquisitions. Other, net in 2022 also includes $176 million of charges related to a voluntary recall within the Nutritional products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net in 2021 also includes costs related to certain litigation.

Schedule of Depreciation, Additions to Property and Equipment, and Total Assets by Segment

	Depreciation						Additions to Property and Equipment (d)						Total Assets
(in millions)	2023		2022		2021		2023		2022		2021		2023		2022		2021
Established Pharmaceuticals	$	104	$	97	$	94	$	185	$	175	$	169	$	3,118	$	2,883	$	2,789
Nutritionals	155		155		151		457		251		174		4,270		3,625		3,425
Diagnostics	499		494		760		750		832		980		7,767		7,985		7,699
Medical Devices	315		311		285		604		335		348		9,029		7,844		7,261
Total Reportable Segments	1,073		1,057		1,290		1,996		1,593		1,671		$	24,184	$	22,337	$	21,174
Other	204		197		201		213		182		201
Total	$	1,277	$	1,254	$	1,491	$	2,209	$	1,775	$	1,872

Schedule of Reconciliation of Segment Assets to Total Assets

(in millions)	2023		2022
Total Reportable Segment Assets	$	24,184	$	22,337
Cash and investments	8,078		10,936
Goodwill and intangible assets	32,494		33,253
All other (e)	8,458		7,912
Total Assets	$	73,214	$	74,438

________________________________________________________

(d)	Amounts exclude property, plant and equipment acquired through business acquisitions.
(e)	All other includes the long-term assets associated with the defined benefit plans of $4.16 billion in 2023 and $3.20 billion in 2022.

Schedule of Net Sales to External Customer by Geographic Areas

	Net Sales to External Customers (f)
(in millions)	2023		2022		2021
United States	$	15,452	$	18,142	$	16,642
Germany	2,345		2,340		2,572
China	2,253		2,133		2,392
India	1,750		1,649		1,561
Switzerland	1,638		1,336		1,313
Japan	1,513		1,932		1,695
Netherlands	1,074		1,111		1,174
All Other Countries	14,084		15,010		15,726
Consolidated	$	40,109	$	43,653	$	43,075

________________________________________________________

(f) Sales by country are based on the country that sold the product.